-
Gilead Seeks Diversification Into Immuno-oncology Space With $11.9 Billion Kite Pharma Acquisition
Monday, August 28, 2017 - 8:59am | 504Read More...In a major push into the immuno-oncology space, Gilead Sciences, Inc. (NASDAQ: GILD), which is primarily into antiviral drug development, specifically for the treatment of HIV, hepatitis B, hepatitis C and influenza, announced a multi-billion dollar deal to buy Kite Pharma Inc (NASDAQ: KITE...
-
Gilead's President Spoke At Goldman Sachs' Global Healthcare Conference This Week: Here Are The Highlights
Thursday, June 11, 2015 - 2:00pm | 794Read More...Gilead Sciences, Inc. (NASDAQ: GILD) President and COO John Milligan spoke to investors at Goldman Sachs' annual Global Healthcare Conference on Tuesday. He addressed the biotech company's growth, drug portfolio, and future prospects. A Good Year Milligan discussed how Gilead's...
